# IP2-ATLANTA (NCT03763253)

> Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03763253
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Imperial College London
- Conditions: Prostate Cancer; Metastatic Prostate Cancer
- Interventions: Standard of Care; Minimally Invasive Ablative Therapy (MIAT); Radical Therapy (Prostatectomy or Radiotherapy)
- Enrollment: 433
- Primary outcome: Prostate cancer on post-standard of care prostate biopsy.
- Primary outcome: Safety (Adverse Events)
- Primary outcome: Progression-free survival (PFS)

## Indexed commentary on IP2-ATLANTA so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=ip2-atlanta-nct03763253